ConductScience.org, home

Gene · 9760

TOX: thymocyte selection associated high mobility group box

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. TOX: thymocyte selection associated high mobility group box. Genes, record 9760. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9760

On this page

Gene

Symbol
TOX
HGNC
Name
thymocyte selection associated high mobility group box
HGNC
NCBI Gene ID
9760
NCBI Gene
HGNC ID
HGNC:18988
HGNC
Ensembl
ENSG00000198846
NCBI Gene
Aliases
KIAA0808, TOX1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
O94900Thymocyte selection-associated high mobility group box protein TOX5260Ensembl, GeneID, HGNC

Source UniProt

Patents61

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4805378 A12026-09-16104O94900Espacenet
JP 2026523341 A2026-07-14563O94900Espacenet
EP 4771137 A12026-07-08101O94900Espacenet
EP 4771157 A12026-07-08101O94900Espacenet
US 12649003 B22026-06-09563O94900Espacenet
JP 2026510339 A2026-04-02101O94900Espacenet
EP 4713451 A22026-03-25101O94900Espacenet
EP 4713452 A22026-03-25101O94900Espacenet
US 12558437 B22026-02-24563O94900Espacenet
EP 4677082 A22026-01-14101O94900Espacenet

1 to 10 of 61

See all 61 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,689

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleTOX papersNewest fiscal year
P30CA008748Cancer Center Support Grant302025
U19AI082630Durable Alteration of the Human Immune system after Infection or Immunotherapy162025
P01AI108545Synergies among inhibitory receptors in tolerance and disease132025
P30CA016672Cancer Center Support Grant132025
P30CA016520Abramson Cancer Center Support Grant112025
P30CA076292Moffitt Cancer Center Support Grant102025
P30CA021765Cancer Center Support Grant (CCSG)82025
R01CA237311EPIGENETIC REPROGRAMMING OF T CELL EXHAUSTION TO ENHANCE TUMOR IMMUNOTHERAPY72025
P01CA214278Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 1962025
P30CA016042Cancer Center Support Grant62025

1 to 10 of 1,689Source NIH's project files

See all 1,689 nih grants

Papers2,030

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Advanced-stage cutaneous T-cell lymphomas show distinct immune profiles in erythroderma vs. tumor lesions.J Dermatol Sci202642810908PubTator, text miningPubMed
TIGIT regulates CD8+T cell exhaustion via the PI3K/AKT-FOXO1-TOX axis in extrahepatic cholangiocarcinoma.Clin Immunol202642810560PubTator, text miningPubMed
T cell exhaustion in sepsis: mechanisms, biomarkers, and immune-reversal strategies.Front Immunol202642756179PubTator, text miningPubMed
Checkpoint-enriched T cells with retained effector-associated features are associated with disease activity in systemic lupus erythematosus.Front Immunol202642746266PubTator, text miningPubMed
Immune dysregulation and stem-like CD8+ T cell enrichment in type 1 diabetes pancreatic lymph nodes.J Clin Invest202642741944PubTator, text miningPubMed
ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer.Nat Immunol202642728401PubTator, text miningPubMed
Disulfidptosis as an immunometabolic rheostat in gastrointestinal cancers: tuning the balance between T Cell exhaustion and immunogenic cell death.Front Cell Dev Biol202642724329PubTator, text miningPubMed
High HBV antigen levels drive loss of vaccine-induced CD8+ T-cell function in carrier mice over time.JHEP Rep202642722105PubTator, text miningPubMed
Corrigendum to 'TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma' [J hepatol (2019) 71(4):731-741; doi: 10.1016/j.jhep.2019.05.015].J Hepatol202642711201PubTator, text miningPubMed
Hypoxia induces cytotoxicity and suppresses cytokine production by CD8□ T cells in cutaneous leishmaniasis.bioRxiv202642620055PubTator, text miningPubMed

1 to 10 of 2,030

See all 2,030 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/9760

GET https://conductscience.org/api/genes/v1/9760/patents?page=2